Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ: APGE )

21.50 +0.33 (+1.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 248,236
Open 21.57
Bid (Size) 19.80 (1)
Ask (Size) 22.25 (1)
Prev. Close 21.17
Today's Range 21.04 - 22.23
52wk Range 14.19 - 25.54
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire

Performance

YTD
+1.27%
+1.27%
1 Month
+24.49%
+24.49%
3 Month
-9.66%
-9.66%
6 Month
+1.27%
+1.27%
1 Year
+1.27%
+1.27%

More News

Read More
7 Biotech Stocks to Get In Now Before Investors Catch On
Via InvestorPlace
Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board
From Apogee Therapeutics, LLC
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics to Participate in Upcoming August Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee, Sagimet Debut This Week In First Big IPOs Of Summer
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.